Table 5 Sensitivity analyses of the associations between MetS and urologic, kidney, prostate, and bladder cancer risk

Excluding participants with history of myocardial infarction and stroke

MetS status

Non-MetS

Ref

Ref

Ref

Ref

MetS

1.32(1.10–1.60)

1.82(1.32–2.51)

1.50(1.06–2.13)

0.92(0.65–1.31)

No. of MetS components

0

Ref

Ref

Ref

Ref

1

0.98(0.68–1.40)

1.11(0.55–2.26)

0.98(0.48–2.03)

0.84(0.47–1.49)

2

1.10(0.77–1.57)

1.68(0.86–3.26)

1.07(0.53–2.16)

0.85(0.48–1.49)

3

1.34(0.93–1.91)

2.18(1.12–4.26)

1.60(0.79–3.21)

0.85(0.47–1.54)

4–5

1.44(0.97–2.11)

2.91(1.45–5.82)

1.45(0.67–3.13)

0.70(0.35–1.41)

_Ptrend

0.003

 < 0.001

0.050

0.446

Excluding participants who developed urologic cancer within the first 2 years of follow-up

MetS status

Non-MetS

Ref

Ref

Ref

Ref

MetS

1.31(1.08–1.59)

1.77(1.26–2.48)

1.49(1.05–2.13)

0.97(0.68–1.37)

No. of MetS components

0

Ref

Ref

Ref

Ref

1

1.00(0.69–1.46)

1.08(0.53–2.19)

0.98(0.47–2.02)

0.96(0.52–1.75)

2

0.97(0.68–1.40)

1.37(0.69–2.70)

0.93(0.46–1.90)

0.84(0.46–1.53)

3

1.21(0.83–1.75)

1.59(0.79–3.18)

1.46(0.72–2.96)

0.95(0.51–1.76)

4–5

1.45(0.98–2.15)

3.01(1.51–6.00)

1.36(0.63–2.94)

0.75(0.37–1.54)

_Ptrend

0.012

 < 0.001

0.095

0.501